DrugPatentWatch Database Preview

RUBRACA Drug Profile

« Back to Dashboard

When do Rubraca patents expire, and what generic alternatives are available?

Rubraca is a drug marketed by Clovis Oncology Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has two hundred and thirty-six patent family members in fifty-two countries.

The generic ingredient in RUBRACA is rucaparib camsylate. One supplier is listed for this compound. Additional details are available on the rucaparib camsylate profile page.

Summary for RUBRACA

International Patents:	236
US Patents:	10
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	43
Clinical Trials:	9
Patent Applications:	45
Drug Prices:	Drug price information for RUBRACA
DailyMed Link:	RUBRACA at DailyMed

Generic Entry Opportunity Date for RUBRACA

NDA:

209115

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for RUBRACA

Drug Class	Poly(ADP-Ribose) Polymerase Inhibitor
Mechanism of Action	Poly(ADP-Ribose) Polymerase Inhibitors

Synonyms for RUBRACA

283173-50-2

6-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-3,10-DIAZATRICYCLO[6.4.1.0?,(1)(3)]TRIDECA-1,4(13),5,7-TETRAEN-9-ONE

6H-Azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-

6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-

6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-

8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON

8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one

8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one

8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE

8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one

8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one

8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one

8237F3U7EH

AC-24390

AG 014699

AG-14447

AG14447

AK317822

AKOS015898427

BDBM50446130

BRD-K88560311-011-01-4

CHEBI:134689

CHEBI:94311

CHEMBL1173055

CS-2785

CTK4G1217

D01SHZ

D10079

DB12332

DTXSID10182563

FT-0696622

GTPL7736

HMABYWSNWIZPAG-UHFFFAOYSA-N

HY-10617A

I10-0690

KB-73984

Kinome_3180

MolPort-028-744-762

NCGC00263173-01

NCGC00263173-03

PF 01367338

PF01367338

PL006099

RPB

Rubraca (TN)

RUCAPARIB

Rucaparib (free base)

Rucaparib (USAN/INN)

Rucaparib [USAN:INN]

Rucaparib(AG-014447)

SCHEMBL844585

Tube725

UNII-8237F3U7EH

Z-3241

ZINC25958

US Patents and Regulatory Information for RUBRACA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes			Y

International Patents for RUBRACA

Country	Patent Number	Estimated Expiration
Austria	508118
Israel	176013
Russian Federation	2012138892
Russian Federation	2413515
Norway	20013313

Supplementary Protection Certificates for RUBRACA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1633724	PA2015016	Lithuania		PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
1633724	13/2015	Austria		PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
1633724	PA2015016,C1633724	Lithuania		PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
1633724	15C0022	France		PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
1633724	213 50005-2015	Slovakia		PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218